SMN1 and proximal spinal muscular atrophy: As newborn screening programs and treatment become increasingly available for SMA, addressing the pathophysiology and management of fatigue and the other ancillary symptoms that are not directly positively affected by SMN1-targeting medications becomes essential to optimize patients’ quality of life and overall health conditions.